JATT ACQUISITION CORP |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.64 USD | +5.22% |
|
+33.23% | -43.14% |
| 2023 | JATT Acquisition Corp Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
| 2023 | Zura Bio Completes Business Combination With JATT Acquisition | MT |
Financials (USD)
| Sales 2021 | - | Sales 2022 | - | Capitalization | 176M |
|---|---|---|---|---|---|
| Net income 2021 | 8M | Net income 2022 | 3M | EV / Sales 2021 | - |
| Net cash position 2021 | 729K | Net Debt 2022 | 342K | EV / Sales 2022 | - |
| P/E ratio 2021 * |
-
| P/E ratio 2022 |
49.6
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 59.06% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +5.22% | ||
| Current month | -43.14% | ||
| Current year | -43.14% |
3 years
4.29
12.38
5 years
4.2912.38
10 years
4.2912.38
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-29 | 4.64 | +5.22% | 282,994 |
| 24-04-26 | 4.41 | +21.82% | 897,979 |
| 24-04-25 | 3.62 | +9.37% | 338,797 |
| 24-04-24 | 3.31 | -4.89% | 849,725 |
| 24-04-23 | 3.48 | +5.14% | 133,183 |
Delayed Quote Nyse, April 29, 2024 at 04:00 pm EDT
More quotes
Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs. Tibulizumab (ZB-106) is an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of TALTZ (ixekizumab) and tabalumab that neutralizes IL-17A and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain (IL-7R) alpha. Torudokimab (ZB-880) is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.
Sector
Investment Holding Companies
| 1st Jan change | Capi. | |
|---|---|---|
| -43.14% | 70.09M | |
| +166.80% | 5.68B | |
| +1.65% | 1.01B | |
| +2.05% | 982M | |
| +41.91% | 872M | |
| +24.28% | 819M | |
| +1.72% | 663M | |
| +1.80% | 610M | |
| -.--% | 600M | |
| +36.55% | 552M |
- Stock Market
- Equities
- JATT Stock
